MAS1 and myositis disease: Myositis autoantibodies (MAs), including myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs), are considered key biomarkers of IIMs, with a prevalence of approximately 70% in patients, helping to classify patients into more homogeneous clinical phenotypes [4].